Cargando…

Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding

Endothelial cells (ECs) grant access of disseminated cancer cells to distant organs. However, the molecular players regulating the activation of quiescent ECs at the premetastatic niche (PMN) remain elusive. Here, we find that ECs at the PMN coexpress tumor necrosis factor–related apoptosis-inducing...

Descripción completa

Detalles Bibliográficos
Autores principales: Riera-Domingo, Carla, Leite-Gomes, Eduarda, Charatsidou, Iris, Zhao, Peihua, Carrá, Giovanna, Cappellesso, Federica, Mourao, Larissa, De Schepper, Maxim, Liu, Dana, Serneels, Jens, Alameh, Mohamad-Gabriel, Shuvaev, Vladimir V., Geukens, Tatjana, Isnaldi, Edoardo, Prenen, Hans, Weissman, Drew, Muzykantov, Vladimir R., Soenen, Stefaan, Desmedt, Christine, Scheele, Colinda L. G. J., Sablina, Anna, Di Matteo, Mario, Martín-Pérez, Rosa, Mazzone, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032608/
https://www.ncbi.nlm.nih.gov/pubmed/36947620
http://dx.doi.org/10.1126/sciadv.add5028
Descripción
Sumario:Endothelial cells (ECs) grant access of disseminated cancer cells to distant organs. However, the molecular players regulating the activation of quiescent ECs at the premetastatic niche (PMN) remain elusive. Here, we find that ECs at the PMN coexpress tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and its cognate death receptor 5 (DR5). Unexpectedly, endothelial TRAIL interacts intracellularly with DR5 to prevent its signaling and preserve a quiescent vascular phenotype. In absence of endothelial TRAIL, DR5 activation induces EC death and nuclear factor κB/p38–dependent EC stickiness, compromising vascular integrity and promoting myeloid cell infiltration, breast cancer cell adhesion, and metastasis. Consistently, both down-regulation of endothelial TRAIL at the PMN by proangiogenic tumor-secreted factors and the presence of the endogenous TRAIL inhibitors decoy receptor 1 (DcR1) and DcR2 favor metastasis. This study discloses an intracrine mechanism whereby TRAIL blocks DR5 signaling in quiescent endothelia, acting as gatekeeper of the vascular barrier that is corrupted by the tumor during cancer cell dissemination.